1001180-21-7

Basic information

• Product Name: tert-Butyl (R)-4-(5-methyl-7-oxo-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazine-1-carboxylate
• Synonyms: tert-Butyl (R)-4-(5-methyl-7-oxo-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazine-1-carboxylate;R)-tert-butyl 4-(5-Methyl-7-oxo-6,7-dihydro-5H-cyclopenta[d]pyriMidin-4-yl)piperazine-1-carboxylate;tert-butyl 4-((R)-6,7-dihydro-5-methyl-7-oxo-5Hcyclopenta[d]pyrimidin-4-yl)piperazine-1-carboxylate;EOS-60388
• CAS NO: 1001180-21-7
• Molecular Formula: C₁₇H₂₄N₄O₃
• Molecular Weight: 332.39746
• Mol File: 1001180-21-7.mol
• Article Data: 16

Chemical Properties

• Boiling Point: 484.5±45.0 °C(Predicted)
• Appearance: /
• Density: 1.222±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 3.61±0.40(Predicted)
• CAS DataBase Reference: tert-Butyl (R)-4-(5-methyl-7-oxo-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-Butyl (R)-4-(5-methyl-7-oxo-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazine-1-carboxylate(1001180-21-7)
• EPA Substance Registry System: tert-Butyl (R)-4-(5-methyl-7-oxo-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazine-1-carboxylate(1001180-21-7)

Safety Data

• Hazardous Substances Data: 1001180-21-7(Hazardous Substances Data)

Usage

General Description

Tert-butyl (R)-4-(5-methyl-7-oxo-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazine-1-carboxylate is a chemical compound with the molecular formula C19H28N4O3. It is a piperazine derivative that is used as an intermediate in the synthesis of pharmaceutical compounds. The tert-butyl group and the carboxylate group make the molecule more stable and less reactive, while the piperazine and the cyclopenta[d]pyrimidin-4-yl moieties contribute to its pharmacological properties. tert-Butyl (R)-4-(5-methyl-7-oxo-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazine-1-carboxylate is utilized in drug development and research for its potential biological activities, such as anti-inflammatory, antiviral, or antitumor effects. It is important to handle this chemical with proper safety precautions and under the guidance of established laboratory protocols due to its potential hazards and reactivity.

Upstream product

• 1295516-49-2 methyl 3-(4,6-dichloropyrimidin-5-yl)butanoate 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 

Downstream Products

• 1001180-45-5 tert-butyl 4-((5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]-pyrimidin-4-yl)piperazine-1-carboxylate 
• 1001201-61-1 tert-butyl 4-((5R,7S)-7-hydroxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazine-1-carboxylate 
• 1001270-26-3 tert-butyl ((S)-2-(4-chlorophenyl)-3-(4-((5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazin-1-yl)-3-oxopropyl)carbamate 
• 1001270-64-9 tert-butyl ((S)-2-(4-chlorophenyl)-3-(4-((5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazin-1-yl)-3-oxopropyl)(isopropyl)carbamate 
• 1097870-39-7 (S)-tert-butyl 2-((S)-1-(4-chlorophenyl)-2-(4-((5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazin-1-yl)-2-oxoethyl)piperidine-1-carboxylate 

Relevant articles and documents

PROCESS FOR MAKING HYDROXYLATED CYCLOPENTYLPYRIMIDINE COMPOUNDS

Provided herein is a process for synthesis of intermediates for ipatasertib related to large scale manufacture of (R)-5-methyl-4-(piperazin-1-yl)-5,6-dihydro-7H-cyclopenta[d]pyrimidin-7-one.

PROCESSES FOR PREPARING (CYCLOPENTYL[d]PYRIMIDIN-4-YL)PIPERAZINE COMPOUNDS

The present disclosure relates to processes for preparing (cyclopentyl[d]pyrimidin-4-yl)piperazine compounds, and more particularly relates to processes for preparing (R)-4-(5-methyl-7-oxo-6,7-dihydro-5H-cyclopenta[d] pyrimidin-4-yl)piperazine and N-protected derivatives thereof, which may be used as an intermediate in the synthesis of Ipatasertib (i.e., (S)-2-(4-chlorophenyl)-1-(4-((5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazin-1-yl)-3-(isopropylamino)-propan-1-one). The present disclosure additionally relates to various compounds that are intermediates employed in these processes.

Synthesis of Akt inhibitor ipatasertib. part 2. Total synthesis and first kilogram scale-up

Herein, the first-generation process to manufacture Akt inhibitor Ipatasertib through a late-stage convergent coupling of two challenging chiral components on multikilogram scale is described. The first of the two key components is a trans-substituted cyc